Zacks: Analysts Expect CytomX Therapeutics Inc (NASDAQ:CTMX) Will Announce Quarterly Sales of $15.11 Million
Equities analysts expect that CytomX Therapeutics Inc (NASDAQ:CTMX) will announce sales of $15.11 million for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for CytomX Therapeutics’ earnings. The lowest sales estimate is $8.00 million and the highest is $24.47 million. CytomX Therapeutics posted sales of $21.34 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 29.2%. The firm is expected to issue its next quarterly earnings results on Wednesday, August 14th.
According to Zacks, analysts expect that CytomX Therapeutics will report full year sales of $69.46 million for the current fiscal year, with estimates ranging from $53.50 million to $90.48 million. For the next fiscal year, analysts anticipate that the company will report sales of $51.61 million, with estimates ranging from $32.52 million to $61.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for CytomX Therapeutics.
CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.22. The business had revenue of $29.49 million during the quarter, compared to analysts’ expectations of $13.59 million. CytomX Therapeutics had a negative return on equity of 73.62% and a negative net margin of 111.27%.
NASDAQ CTMX traded up $0.17 during midday trading on Wednesday, hitting $12.25. The company had a trading volume of 20,034 shares, compared to its average volume of 459,546. The stock has a market cap of $562.76 million, a P/E ratio of -6.11 and a beta of 0.64. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.22. The business has a 50-day moving average of $10.69. CytomX Therapeutics has a twelve month low of $8.94 and a twelve month high of $27.20.
Institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc increased its stake in shares of CytomX Therapeutics by 18.6% in the 4th quarter. Legal & General Group Plc now owns 8,342 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 1,306 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of CytomX Therapeutics by 84,072.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,259 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 9,248 shares during the last quarter. Deltec Asset Management LLC bought a new position in shares of CytomX Therapeutics in the 1st quarter valued at $129,000. Metropolitan Life Insurance Co. NY increased its stake in shares of CytomX Therapeutics by 376.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,479 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 10,650 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its stake in shares of CytomX Therapeutics by 21.5% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 14,700 shares of the biotechnology company’s stock valued at $334,000 after purchasing an additional 2,600 shares during the last quarter. Institutional investors own 81.83% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Recommended Story: Commodities
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.